SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Eric Dieperink, Christine Pocha, Paul Thuras, Astrid Knott, Samuel Colton, Samuel B. Ho, All-Cause Mortality and Liver-Related Outcomes Following Successful Antiviral Treatment for Chronic Hepatitis C, Digestive Diseases and Sciences, 2014, 59, 4, 872

    CrossRef

  2. 2
    Kian Bichoupan, Valerie Martel-Laferriere, David Sachs, Michel Ng, Emily A. Schonfeld, Alexis Pappas, James Crismale, Alicia Stivala, Viktoriya Khaitova, Donald Gardenier, Michael Linderman, Ponni V. Perumalswami, Thomas D. Schiano, Joseph A. Odin, Lawrence Liu, Alan J. Moskowitz, Douglas T. Dieterich, Andrea D. Branch, Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response, Hepatology, 2014, 60, 3
  3. 3
    Brian L. Pearlman, Carole Ehleben, Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor, Hepatology, 2014, 59, 1
  4. 4
    K. Hara, M. M. Rivera, C. Koh, M. DeMino, S. Page, P. R. Nagabhyru, B. Rehermann, T. J. Liang, J. H. Hoofnagle, T. Heller, Sequence Analysis of Hepatitis C Virus From Patients With Relapse After a Sustained Virological Response: Relapse or Reinfection?, Journal of Infectious Diseases, 2014, 209, 1, 38

    CrossRef

  5. 5
    Naga Suresh Veerapu, Su-Hyung Park, Damien C. Tully, Todd M. Allen, Barbara Rehermann, Trace amounts of sporadically reappearing HCV RNA can cause infection, Journal of Clinical Investigation, 2014, 124, 8, 3469

    CrossRef

  6. 6
    O. C. Pereira, J. J. Feld, Editorial Commentary: Sustained Virologic Response for Patients With Hepatitis C-Related Cirrhosis: A Major Milestone, but Not Quite a Cure, Clinical Infectious Diseases, 2013, 57, 2, 237

    CrossRef